Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Breault, US
Glen G. Breault, Hartland, MI US
| Patent application number | Description | Published |
|---|---|---|
| 20110309644 | LATCH STRIKER WITH INTEGRAL LIGHT MECHANISM - A latch striker may be used in a vehicle to hingedly attach a door, such as a glove box door to an instrument panel of a vehicle such that the door may be selectively opened and closed. The latch striker of the present embodiment may comprise a body, a latch bar attached to the body at an end of the body. The latch bar is capable of removably securing to a catch mechanism of the vehicle. The latch striker may further comprise a mounting device formed in a portion of the body substantially opposite the end of the body, the mounting device is capable of attaching to the vehicle, and a light mechanism secured to the body. | 12-22-2011 |
Gloria Breault, Waltham, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20100152441 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS - The present invention relates to compounds that demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans. In particular this invention relates to compounds useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans. | 06-17-2010 |
| 20110092495 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS - The present invention relates to compounds that demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans. In particular this invention relates to compounds useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans. | 04-21-2011 |
John P. Breault, New Britain, CT US
| Patent application number | Description | Published |
|---|---|---|
| 20090114678 | RETRACTABLE SEALANT DISPENSING APPARATUS FOR SQUEEZE TUBE - A dispensing apparatus provides for the dispensing of product from a collapsible tube. The apparatus includes a body for supporting the tube. The body has a forward end for accommodating a dispensing end of the tube and rearward end for accommodating a closed end of the tube. An elongate actuatable plunger is supported by the body. The plunger includes an elongate rod and a base attached to the rod. Actuating means is provided for effecting movement of the plunger in a first direction along the body for engagement with the collapsible tube wall thereby deforming the tube wall and dispensing the contents of the tube from the dispensing end. The actuating means also provides for retractable movement of the plunger in the second direction opposite the first direction. The base is positioned on the rod for dispensing engagement with the tube upon movement of the plunger in the first direction and movable out of dispensing engagement with the tube upon in a second direction. | 05-07-2009 |
| 20100313996 | HAND HELD PERISTALTIC PUMP FOR DISPENSING FLUID FROM A RIGID CONTAINER - A fluid dispensing apparatus includes an operable peristaltic pump. The pump supports a rigid container which includes an aggressive fluid which is to be dispensed from the container. A vent tube and a dispensing tube extends from the container through the pump. Operation of the pump causes fluid to be pumped out from the container through the dispensing tube while air is pumped into the container through the vent tube. This equalizes pressure in the container and allows fluid to be dispensed from a rigid container. | 12-16-2010 |
Judith A. Breault, Charlotte, NC US
| Patent application number | Description | Published |
|---|---|---|
| 20090327154 | SYSTEMS, METHODS, AND COMPUTER PROGRAM PRODUCTS FOR MONITORING COLLATERALIZATION OF PUBLIC-DEPOSIT ACCOUNTS - The present invention provides systems, methods, and computer program products for monitoring collateral positions of public-deposit accounts so as to efficiently pledge collateral to under-collateralized positions and release collateral from over-collateralized positions. For example, when a customer deposits additional funds, which results in an uninsured balance that exceeds the allocated collateral, the present invention may identify that account as being under-collateralized, determine the pledge amount required to properly collateralize the account, and then create, submit and track a pledge request that corresponds to the required pledge amount. Likewise, when a customer withdraws funds from a public-deposit account, which results in an uninsured balance that is less than the allocated collateral, the present invention may identify that account as being over-collateralized, determine the appropriate release amount, and then create, submit and track a release request that corresponds to the determined release amount. | 12-31-2009 |
Lyne Breault, Roslindale, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20100003258 | FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS - Monoclonal antibodies that bind and inhibit activation of fibroblast growth factor receptor 3 (FGFR3) are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of FGFR3. | 01-07-2010 |
| 20100173361 | Hepatocyte Growth Factor (HGF) Binding Proteins - The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors. | 07-08-2010 |
| 20110229462 | Hepatocyte Growth Factor (HGF) Binding Proteins - The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors. | 09-22-2011 |
| 20110236377 | Hepatocyte Growth Factor (HGF) Binding Proteins - The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors. | 09-29-2011 |
| 20110256154 | ANTI-ERBB3 ANTIBODIES - Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3. | 10-20-2011 |
Lyne Breault, Toslindale, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20100173362 | Hepatocyte Growth Factor (HGF) Binding Proteins - The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors. | 07-08-2010 |
Timothy J. Breault, Huntersville, NC US
| Patent application number | Description | Published |
|---|---|---|
| 20090063361 | Risk and Reward Assessment Mechanism - A data driven and forward looking risk and reward appetite methodology for consumer and small business is described. The methodology includes customer segmentation to create pools of homogeneous assets in terms of revenue and loss characteristics, forward looking simulation to forecast expected values and volatilities of revenue and loss, and risk and reward optimization of the portfolio. One methodology used for modeling revenue and loss is a generalized additive effect decomposition model to fit historical data. Based on the model, a segmentation procedure is performed, which allows for creation of groups of customers with similar revenue and loss characteristics. An estimation procedure for the model is developed and a simulation strategy to forecast and simulate revenue and loss volatility is developed. Efficient frontier curves of risk (e.g., return volatility) and reward (e.g., expected return) are created for the current portfolio under various economic scenarios. | 03-05-2009 |
| 20100293107 | Risk and Reward Assessment Mechanism - A data driven and forward looking risk and reward appetite methodology for consumer and small business is described. The methodology includes customer segmentation to create pools of homogeneous assets in terms of revenue and loss characteristics, forward looking simulation to forecast expected values and volatilities of revenue and loss, and risk and reward optimization of the portfolio. One methodology used for modeling revenue and loss is a generalized additive effect decomposition model to fit historical data. Based on the model, a segmentation procedure is performed, which allows for creation of groups of customers with similar revenue and loss characteristics. An estimation procedure for the model is developed and a simulation strategy to forecast and simulate revenue and loss volatility is developed. Efficient frontier curves of risk (e.g., return volatility) and reward (e.g., expected return) are created for the current portfolio under various economic scenarios. | 11-18-2010 |